Sutent Approved For Advanced Pancreatic Neuroendocrine Tumors, USA
Sutent (sunitinib) has been approved by the FDA for treating advanced pancreatic neuroendocrine tumors. Specifically, the medication has been given the green light for patients whose tumors cannot be surgically removed, or for those whose cancer has metastasized. This is the second drug, after Afinitor, to be approved for the same indication this month. Advanced (progressive) pancreatic ...

FDA Sets Meeting Date In Early June To Discuss Re-Submission Of Pixantrone NDA For Accelerated Approval
Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced today that it will meet with the U.S. Food and Drugs Administration's (the "FDA") Office of Oncology Drug Products in early June to discuss the re-submission of CTI's New Drug Application ("NDA") for pixantrone for accelerated approval to treat patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL")...